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The tumor suppressor p53 protein controls cell cycle and plays a vital role in 
preserving DNA integrity. p53 is activated by varied stress signals and the distribu-
tion of p53 between the different subcellular compartments depends on the cellular 
stress milieu. DNA repair pathways protect cells from damage that can lead to DNA 
breaks. The multi-functional p53 protein promotes DNA repair both directly and 
indirectly through multiple mechanisms; it accomplishes multi-compartmental 
functions by either numerous p53-controlled proteins or by its inherent biochemical 
activities. Accumulating evidence supports the contribution of p53 in the mainte-
nance of the genomic integrity and in various steps of the DNA damage response, 
through its translocation into nucleus and mitochondria. p53 may also be utilized 
by viral polymerases in cytoplasm to maintain genomic integrity of viruses, thus 
expanding the role of p53 as a ‘guardian of the genome’. We summarize recent  
findings highlighting roles of p53 in DNA repair.
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1. Introduction
Humans are persistently exposed to various chemical and physical agents that 
have the potential to damage genomic DNA, such as, irradiation (IR), ultraviolet 
(UV) light, reactive oxygen species (ROS), et cetera [1]. The integrity and survival 
of a cell is critically dependent on genome stability and mammalian cells have 
established multiple pathways to repair different types of target DNA lesions to 
safeguard the genome from deleterious consequences of various kinds of stresses 
[2]. The significance of the DNA repair in the protection of genomic stability is 
highlighted by the fact that many proteins/factors involved have been preserved 
through evolution [3].
DNA damage, induced by endogenous and exogenous agents, is a common event 
and must undergo a variety of DNA damage repair in order to ensure the faithful 
transfer of genetic information during cell division [3]. Four main DNA polymer-
ases are involved with nuclear DNA replication: DNA polymerase α, β, δ and ε [1] 
(Figure 1). DNA repair pathways, which are also recognized as guardians of the 
genome, protect cells from numerous damages leading to DNA breaks [4]. Failure 
to restore DNA lesions or inappropriate repair of DNA damage give rise to genomic 
instability, which is a hallmark of cancer. Remarkably, mild and massive DNA 
damage are differentially integrated into the cellular signaling networks and, in 
consequence, provoke different cell fate decisions. After mild damage, the cellular 
response is cell cycle arrest, DNA repair, and cell survival, whereas severe damage, 
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drives the cell death response. The inability of the DNA damage response (DDR) 
to repair following endogenous and exogenous insults can lead to (i) an accumula-
tion of errors in genomic DNA, (ii) subsequent malignant transformation, (iii) 
cancer progression and (iv) further impairment of the DNA repair capacity. DNA 
repair mechanisms comprise the detection and deletion (excision) of the lesion, the 
rejoining of DNA ends and the restoration of the complementary sequence based on 
a DNA template.
Since cancer cells typically have many mutations compared to a non-cancer cell, 
it was proposed that one of the earliest changes in the development of a cancer cell 
is a mutation that increases the spontaneous mutation rate [5]. The presence of a 
“mutator phenotype” could increase the acquisition of alterations that could lead to 
enhanced drug resistance limiting the effectiveness of anti-cancer drug treatment.
Viral infection is characterized by the high genetic variability found in virus 
populations [6]. This phenomenon is attributed to the inaccuracy of the replication 
machinery that is unique to the viral life cycle. Virulence, pathogenesis and the abil-
ity to develop effective antiretroviral drugs and vaccines are largely dependent on 
genetic diversity in viruses [7]. Retroviruses are RNA viruses that replicate through 
a DNA intermediate in a process catalyzed by the viral reverse transcriptase (RT) 
in cytoplasm (Figure 1) [7]. Human immunodeficiency virus type 1 (HIV-1), the 
etiological agent of AIDS, exhibits exceptionally high mutation frequencies [8]. The 
accepted explanations for the inaccuracy of HIV-1 RT are the relatively low fidelity 
of the enzyme during DNA synthesis and the deficiency of intrinsic proofreading 
activity. A strong mutator phenotype is also observed for herpes viral DNA poly-
merase mutants with reduced intrinsic 3′ → 5′ exonuclease activity [9].
Mitochondrial DNA (mtDNA) alterations have been associated with various 
human diseases with impaired mitochondrial function [10]. Mitochondrial DNA 
polymerase γ (pol γ) is responsible for replication of mtDNA and is implicated in all 
repair processes (Figure 1) [11]. Mitochondrial DNA is prone to mutations, since 
it is localized near the inner mitochondrial membrane in which reactive oxygen 
Figure 1. 
Sub-cellular localization of eukaryotic and retroviral DNA polymerases.
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species are generated. Additionally, mtDNA lacks histone protection and the highly 
efficient DNA repair mechanisms [12]. The mutation rate of mtDNA is estimated to 
be about 20–100-fold higher than that of nuclear DNA [13]. The mutagenic mecha-
nisms were shown to be replication errors caused by mis insertion (as a result of a 
dNTP excess), or decreased proofreading efficiency [14, 15].
Thus, in various compartments of the cell, enhanced DNA replication fidelity is 
a vital activity for the preservation of genomic stability for many organisms.
2. DNA repair
Genomic integrity of the cell is crucial for the successful transmission of 
genetic information to the offspring and its survival [16]. DNA is constantly being 
damaged. Essentially, DNA lesions can occur in two major ways, affecting either 
a single-stranded break (SSB) or double-stranded (DSB) or mono-adducts and 
inter-strand crosslinks, respectively. To combat this, eukaryotes have developed 
complex DNA damage repair (DDR) pathways (Figure 2). The active pathways for 
DNA repair are base excision repair (BER), nucleotide excision repair (NER), and 
mismatch repair MMR for SSB repair, whereas homologous recombination (HR) 
and non-homologous end-joining (NHEJ) for DSB repair [16]. Nucleotide excision 
repair (NER) removes a variety of helix-distorting lesions such as typically induced 
by UV irradiation, whereas base excision repair (BER) targets oxidative base modi-
fications. Mismatch repair (MMR) scans for nucleotides that have been erroneously 
inserted during replication. The most deleterious types of damage in DNA are DSBs 
that are typically induced by IR and resolved either by NHEJ or by HR, whereas 
RECQ helicases assume various roles in genome maintenance during recombination 
repair and replication.
A low fidelity of DNA synthesis in various compartments of the cell by main 
replicative DNA polymerases leads to genomic instability (mutator phenotype) 
[17]. The errors produced during DNA synthesis could result from three fidelity 
Figure 2. 
DNA damage and repair mechanisms. Various DNA damaging agents cause a range of DNA lesions with 
different outcomes at both the genomic and cellular levels. Each are corrected by a specific DNA repair 
mechanism, namely, base-excision repair (BER), nucleotide excision repair (NER), homologous recombination 
(HR)/non-homologous end-joining (NHEJ) or mismatch repair (MMR).
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determining processes: a) nucleotide misinsertion into the nascent DNA, b) lack 
of exonucleolytic proofreading activity, that is, the mechanism to identify and 
excise incorrect nucleotide incorporated during DNA synthesis, and c) extension of 
mismatched 3′-termini of DNA (Table 1) [18].
Incorrectly repaired DNA lesions can lead to mutations, genomic instabil-
ity, changes in the regulation of cellular functions, progression of cancer and 
premature aging. Cells can repair the large variety of DNA lesions through a 
variety of sophisticated DNA-repair machineries, recognizing and activating 
battery of proteins/factors for the repair of damaged DNA. DNA replication is 
a complex process influenced by numerous proteins/factors. The most impor-
tant part of the DNA damage response is the activation of tumor repressor p53 
protein [18].
3. Tumor suppressor p53 protein and DNA repair
The p53 represents a major factor for the maintenance of genome stability 
and for the suppression of cancer [19, 20]. The p53 protein is commonly referred 
to as the “guardian of the genome” due to its activities directed at maintaining 
genomic stability through the repair of damaged DNA [19]. Mutations in p53 
are the most frequent molecular alterations detected in all human cancers [21]. 
Approximately 50% of human tumors harbor p53mutations while the remaining 
malignancies expressing wtp53 display functional inactivation of the p53 path-
way [22]. The loss of the functional p53 may be responsible for genetic variability 
and the development of cancer [22]. Mutations in p53 result in a loss of its physi-
ological function, accompanied by the accumulation of a novel gain-of function 
protein [23].
Under normal conditions within the cell, p53 is maintained at low levels by 
the E3 Ubiquitin ligase MDM2, mediating p53 proteasomal degradation [23]. In 
response to exposure to various endogenous and exogenous stress signals (such as 
DNA damage, oncogene activation, hypoxia, and nutrient depletion), the protein is 
stabilized and functionally activated by a series of post-translational modifications 
(e.g., phosphorylation, acetylation) resulting in p53 accumulation at nuclear and 
Biochemical properties of cellular DNA polymerases
Function 3′ → 5′ exonuclease Proofreading
Nuclear DNA polymerases
α primase no no
β repair no no
δ Lagging DNA synthesis, 
repair
yes yes




γ DNA synthesis yes yes
Retroviral DNA polymerase
HIV-1 RT DNA synthesis no no
Table 1. 
Biochemical properties of eukaryotic and retroviral DNA polymerases.
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extra-nuclear sites [21, 24]. Activated p53 is a pleiotropic regulator and, as a tran-
scription factor, binds to specific DNA sequences thereby regulating the expression 
of plethora of target genes controlling proliferation, senescence, DNA repair, and 
cell death. p53 is involved in diverse cellular processes including cell cycle arrest 
(thus preventing the replication of damaged DNA allowing time for the cells to 
repair DNA), apoptosis (for eliminating cells that contained excessive and irrepa-
rable damaged DNA), or DNA-damage repair (Figure 3) [20, 23]. These processes 
together protect the organism from genetically unstable cells that drive cancer.
p53 exhibits the functional heterogeneity in its basal (non-induced) state and 
under various p53 inducible circumstances [20]. Increasing evidences suggest 
various “non-transcriptional functions” of p53, that can contribute to tumor sup-
pressor activity [25]. p53 may modulate DNA repair through processes, which are 
independent of its transactivation function. p53 is actively transported between the 
nucleus and cytoplasm. Furthermore, p53 translocate to mitochondria [26]. p53 can 
directly interact with DNA repair related cellular factors [27]. The origin, duration, 
intensity of the stress signals, the interaction with other cellular or viral proteins, 
and stress-mediated subcellular localization of p53 determines the outcome of the 
p53 response, namely, its pro- or anti-survival functions [28]. p53 protein executes 
multi-compartmental functions in the cell by either numerous p53-regulated 
proteins or by its intrinsic biochemical activities [28].
3.1 p53 and DNA repair in nucleus
The functioning of the eukaryotic genome relies on effective and accurate 
DNA replication and repair [2]. DNA replication in the nucleus of eukaryotic 
cells employs DNA polymerases (pols) α, β, δ, and ϵ, that are the key enzymes 
required to maintain the integrity of the genome under all these circumstances 
[1, 3]. However, the maintenance of genomic integrity is complicated by the fact 
that the genome is persistently challenged by a variety of endogenous and exog-
enous DNA-damaging factors [4]. DNA lesion can block DNA replication, which 
can lead to double-strand breaks (DSB) or alter base coding potential, leading 
to mutations. The accumulation of damage in DNA can affect gene expression 
leading to the malfunction of many cellular processes [4]. Various DNA repair 
systems operate in cells to remove DNA lesions, and several proteins are known to 
be the key components of these repair systems.
The presence of p53 was demonstrated in different nuclear compartments and 
suggested that the p53 population not engaged in transcriptional regulation could 
exert functions other than induction of growth arrest or apoptosis and directly par-
ticipate in processes of repair [25]. p53 mediating various activities are correlated 
with the levels of the p53 protein in the cells [27, 29]. The non-genotoxic stress may 
include a long-lasting, moderate accumulation of p53 in nucleus. Conversely, acute 
genotoxic stress may induce rapid and transient accumulation of very high levels of 
p53 with preferential activation of target genes involved in apoptosis [29]. There is a 
possibility that both transcriptional and transcription-independent pathways act in 
synergy thereby amplifying the potency of involvement of p53 in DNA repair.
p53 localized in cell nuclei in response to replication stress actively participate in 
various processes of DNA repair and DNA recombination via its ability to interact 
with components of the repair and recombination machinery and by its various 
biochemical activities [30, 31]. Both in vitro and in vivo data suggest an intricate 
relationship between the biochemical activities of p53 in DNA replication and 
recombination. The notion that p53 plays a role in DNA repair pathways in vivo 
is supported by the observation that p53 knockout mice exhibit an increase in 
chromosomal abnormalities and a deficiency in global genomic repair [32]. p53 is 
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involved in almost all nuclear DNA repair pathways including BER, NER, MMR, 
NHEJ and HR [32]. The transcription-independent functions play a prominent role 
as a facilitator of DNA repair by halting the cell cycle to allow time for the repair 
machineries to restore genome stability [25].
The C-terminal 30 amino acids of p53 were shown to recognize several DNA 
damage-related structures.
In addition, full range of various intrinsic biochemical features of the p53 pro-
tein support its possible roles in DNA repair. After DNA damage: (a) p53 is able to 
recognize and bind sites of DNA damage, such as ssDNA and dsDNA ends [33, 34], 
(b) p53 catalyzes DNA and RNA strand transfer and promotes the annealing of 
complementary DNA and RNA single-strands [35, 36], (c) p53 binds insertion/dele-
tion mismatches and bulges [37], (d) p53 binds to three-stranded heteroduplex joints 
and four-stranded Holliday junction DNA structures with localization specifically at 
the junction, suggesting that p53 directly participates in recombination repair [38], 
(e) it can bind DNA in a non-sequence-specific manner [39], (f) p53 exhibits a Mg2+ 
dependent 3′ → 5′ exonuclease activity [40–43].
Noticeably, the same central region within p53, where tumorigenic mutations are 
clustered, recognizes DNA sequence specifically, is required for junction-specific 
binding of heteroduplex joints and is necessary and sufficient for the 3′ → 5′ exo-
nuclease activity on DNA [28]. In addition to p53’s biochemical activities, numerous 
reports on physical and functional protein interactions further strengthened the 
proposal of a direct role of p53 in BER, NER, and DSB repair.
Figure 3. 
In response to various endogenous and exogenous stress signals, the activated p53 arrests the cell cycle until the 
DNA damage is repaired thereby preventing the cancer. If the DNA damage cannot be repaired apoptosis occurs 
for eliminating cells that contained excessive and irreparable damaged DNA.
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a. Oxidative DNA damage is largely repaired by the BER pathway. p53 might 
directly facilitate BER mainly via association with BER components. Wtp53 
directly enhanced BER activity measured both in vitro and in vivo [44]. 
Genotoxic stress induced a p53-dependent modulation in BER activity through-
out the cell cycle. The idea that p53 is directly involved in BER is supported 
by various studies: BER activity in cell extracts correlates with levels of 
purified wtp53 [29], the ability of p53 to augment BER activity is correlated 
with its ability to interact directly both with AP endonuclease and with DNA 
Polymerase β [27, 45]. Hot-spot tumor-derived p53 mutants do not significantly 
enhance BER, supporting the possibility that the stimulatory effect of wtp53 
may contribute to its ability to suppress tumorigenesis. Based on these results, 
p53 stabilization of the DNA pol β–AP-DNA complex is likely to be the mecha-
nism underlying the stimulation of BER by p53 [27].
The cellular response depends on the dose of genotoxic agent introduced to the 
cells. Increasing doses of genotoxic agents cause the accumulation of acti-
vated p53 that determines the onset of BER or apoptosis. Low doses of DNA 
damaging agent resulted in the enhancement of p53-dependent BER activity 
whereas high levels induced different p53 post-translational modifications that 
down regulate BER pathway and instead provoked an apoptotic response [29]. 
The quantitative changes in p53 protein level were associated with qualitative 
changes in p53 phosphorylation status. In all, this may indicate that increasing 
doses of genotoxic agents cause the accumulation of activated p53 that deter-
mines the onset of BER or apoptosis.
b. NER is an important DNA repair process that detects and eliminates lesions 
including both chemical alteration and structural distortion of the DNA helix 
(e.g., photoproducts induced by UV irradiation and other bulky lesions) [25]. 
The NER pathway retains two damage detection pathways: Transcription 
Coupled Repair (TC-NER) and Global Genome Repair (GG-NER), depending 
on the mode of damage recognition in the entire genome versus actively tran-
scribed regions [46–48]. TC-NER detects and removes transcription blocking 
lesions in transcribed sections of the genome; triggered when a lesion inhibits 
transcription elongation by RNA polymerase II, thereby preventing cell death. 
GGR-NER detects lesions across the whole genome, including non-transcribed 
regions. Upon lesion detection by either the TC or GG arm, repair proceeds via 
a final common pathway [25]. The role of p53 in promoting GG-NER is more 
consistent compared to p53 function in TC-NER. p53 facilitates NER by pro-
moting lesion recognition or detection by recruiting the p300 histone acetylase 
to damage sites, which acetylates the histone H3, leading to global chromatin 
relaxation and increased lesion accessibility making an additional contribution 
to the maintenance of genome stability [46–47].
Pathogenic mutations in the GG components XPC and DDB2 (XPE) result 
in xeroderma pigmentosum (XP) a disease characterized by increased UV-
sensitivity and skin cancer incidence [46]. Conversely, mutation in TC genes 
result in Cockayne’s syndrome that is characterized by neurological abnormali-
ties but no increase in skin cancer incidence. Some NER proteins, particularly 
the GG damage recognition proteins, can decide a cell’s fate by triggering the 
initiation of the repair pathway or by signaling apoptosis [46]. Therefore, if the 
GG pathway is defective, neither DNA repair nor apoptosis occurs, resulting 
in a cancer cell containing high levels of UV-induced mutations that does not 
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undergo apoptosis. How this non-transcriptional function of p53 contributes 
to tumor suppression is unclear.
c. DNA mismatch repair (MMR) is an important DNA repair pathway, which 
facilitates removal of incorrect nucleotides incorporated during replication. 
p53 facilitates excision of incorrect nucleotides produced from the error prone 
nature of DNA polymerases and misincorporation of the incorrect base [25]. 
Mismatched bases can be either a G/T or A/C pair. To initiate MMR a nick 
in the DNA either 5′ or 3′ to the mismatch must occur. Proteins that bind the 
mismatch in humans are E. coli MutS homologs. MSH2 is a major component 
of the MMR MSH2-MSH6 complex and is a known to be transcriptionally 
upregulated by p53 following UV [49]. In vitro studies established that the 
MSH2–MSH6 complex can enhance the binding of p53 to DNA substrates with 
topological distortions, and this activity depends on the phosphorylation state 
of p53(S392) [50, 51]. Connections between p53 and MMR have been made in 
various systems demonstrating a role for MMR proteins in influencing p53-
related processes. p53 and MMR proteins can function synergistically in mice, 
as Msh2−/− p53−/− females arrested as embryos and they quickly developed 
tumors relative to the single-mutant animals [52]. p53 signaling was shown 
to be suppressed in MSH2-deficient cells [53]. While these p53-dependent 
mechanisms have been linked to MMR regulation, MSH2 has been implicated 
in a variety of repair pathways and it is necessary to determine if p53 function 
is pertinent. An interesting notion is that, p53 interacts with and transcription-
ally regulates its gene target in MMR. Further studies are needed to define if 
p53 transcription-dependent and independent functions work alongside in 
MMR or whether these functions are separate and dependent on the cellular 
insult or pathway choice.
d. Mutator phenotypes (with the potential for cancer progression) have been 
reported for cells that lack a proofreading 3′ → 5′ exonuclease activity associ-
ated with the DNA polymerase [54]. Excision of incorrectly polymerized 
nucleotides by exonucleases is an imperious mechanism diminishing the 
errors during DNA polymerization [55]. Certain organisms with a deficiency 
of exonucleolytic proofreading, have an increased susceptibility to cancer, 
especially under conditions of stress. Because the misincorporation of non-
complementary dNTPs during DNA replication represents a chief mechanism 
of gene mutation [56], the removal of the wrong nucleotides from DNA is 
critical for genomic stability. The intrinsic limited accuracy of DNA polymer-
ases and the imbalance of intracellular dNTP pools are the two most important 
factors responsible for DNA replication errors [57, 58]. The proofreading for 
such replication errors by the 3′ → 5′ exonuclease activity associated with 
the DNA replication machinery is extremely important in reduction of the 
occurrence of mutations. Interestingly, the mammalian DNA pol α, an enzyme 
considered to be responsible for the lagging strand replication [59], lacks the 
3′ → 5′ exonuclease proof-reading activity and is prone to making replication 
errors [60].
Three steps, base selection, exonucleolytic proofreading, and DNA elongation, 
ensure the high fidelity of DNA replication. wtp53 exhibits an intrinsic 3′ → 5′ 
exonuclease activity. wtp53, co-located with the DNA replication machinery 
[61], specifically interacts with pol α and has been shown to preferentially 
eliminate mismatched nucleotides from DNA with its 3′ → 5′ exonuclease ac-
tivity, thereby enhancing the DNA replication fidelity of pol α in vitro [41].
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Hydroxyurea (HU), an inhibitor of ribonucleotide reductase involved in the 
de novo synthesis of deoxynucleotides, was used to induce dNTP pool imbal-
ance and to cause mutations in the cells due to misincorporation of unpaired 
deoxynucleotides into DNA [62]. The examination of the rates of HU-induced 
mutations in H1299 (p53-null) and H460 (wtp53) cells discovered substan-
tially augmented mutation rates in H1299 cells. Furthermore, the HU-induced 
mutation frequency was significantly reduced by introduction of wtp53 
expression vector into the p53-null H1299 cells. Thus, wtp53 expression was 
associated with a reduction of mutations caused by replication errors under the 
stress of dNTP pool imbalance [62].
The functional interaction of DNA polymerase and exonuclease activity was 
observed with p53/pol-prim complex. p53-containing DNA pol-prim complex 
excised preferentially a 3′-mispaired primer end over a paired one and replaced 
it with a correctly paired nucleotide [63]. In contrast, a pol-prim complex 
containing the hot spot mutant p53R248H did not display exonuclease activity 
and did not elongate a mispaired 3′-end, representing that the p53 exonuclease 
from the p53/pol-prim complex was indispensable for the subsequent elonga-
tion of the primer by DNA polymerase. These findings support the view that 
p53 might fulfill a proofreading function for pol-prim and suggest that the 
defect in proofreading function of p53 may contribute to genetic instability 
associated with cancer development and progression [63].
e. DSBs are the most severe type of DNA damage, and these DSBs generated at 
the replication fork are repaired by two principal repair pathways: homology-
based repair (HR) and non-homologous end-joining (NHEJ) [25, 31]. 
Furthermore, replication blocking lesions such as bulky adducts are subject 
to HR repair, thereby rescuing the replication fork. HR is considered the most 
error-free pathway, because sister chromatids are the preferred template, how-
ever, it can also produce genetic instability upon up- or down-regulation [25].
Depending on the type and quality of the DSB repair pathway involved, the 
repair process may end up with deletions, loss of heterozygosity, and chromo-
somal translocations which may accelerate the multistep process of tumori-
genesis. p53 can control HR in vitro by specific recognition of the heteroduplex 
intermediates, and in vivo by modulating the functions of different HR-specific 
proteins [38, 64]. Numerous groups detected that wtp53 represses HR on both 
extra-chromosomal and intra-chromosomal DNA substrates by at least one 
to two orders of magnitude [31]. Conversely, inactivation of p53 by muta-
tion or complex formation by viral proteins increased HR by several orders of 
magnitude. Importantly, experiments with p53 mutants revealed severe HR 
inhibitory defects for all tested hotspot mutants. Mutant p53s which are known 
to reduce or even abolish p53’s transcriptional transactivation and cell cycle 
regulatory capacity, did not significantly affect HR inhibition [65, 66]. These 
discoveries confirmed that p53 activities in transcriptional transactivation and 
checkpoint control are separable from its functions in homology-based DSB 
repair and provided undoubted proof for a direct role of p53 in HR [67].
p53 prevents the accumulation of DSBs at stalled-replication forks induced by 
UV or hydroxyurea (HU) treatment. When DNA replication is blocked, p53 
becomes phosphorylated on serine 15 and associates with key enzymes of HR 
such as, Rad51, and Rad54 [68, 69]. Notably, during replication arrest p53 re-
mains inactive in transcriptional transactivation, further supporting the direct 
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involvement in HR regulatory functions unrelated to transcriptional transacti-
vation activities.
p53 preferentially represses HR between certain mispaired DNA sequences. 
p53 specifically recognizes preformed heteroduplex joints structurally resem-
bling early recombination intermediates, when comprising these mispairings 
[68]. p53 is able to attack DNA by 3′–5′ exonuclease activity principally during 
Rad51-mediated strand transfer and to display a DNA substrate preference for 
heteroduplex recombination intermediates with a further enhancement of the 
exonucleolytic activity for mispaired as compared to correctly paired hetero-
duplex DNA [38].
Highlighting the significance of p53 DNA interactions in the regulation of 
strand exchange events, p53 inhibits branch migration of Holliday junctions 
(HJs) [25, 31]. p53 recognizes this HJs -like structure and controls the genera-
tion and branch migration of the replication fork as well as its resolution, to 
prevent error-prone DSB repair and to cause replication pausing until the DNA 
lesion is repaired.
f. Mammalian cells repair the majority of double-strand breaks by NHEJ [69, 70] 
which is regarded as principally inaccurate process. The role of p53 in NHEJ 
remains unclear. p53 has an inhibitory effect on error-prone NHEJ but not 
error-free NHEJ [71], thereby suppressing genomic instability arising from low-
fidelity repair. Remarkably, after the exposure to IR, DSB rejoining increases 
with loss of wtp53function. Inhibition of in vitro end-joining was observed with 
the oncogenic mutant p53(175H), whereas the phosphorylation-mimicking 
mutant p53(15D) failed to inhibit, thereby providing evidence for possible role 
of phosphorylated p53 in the regulation of NHEJ [72].
Various in vitro and in vivo studies have shown that p53 can rejoin or ligate 
compatible ends of DNA with DSBs [68, 70]. Evidently, p53 has several ge-
netic interactions with components of the NHEJ pathway that are exhibited by 
downstream effects on cellular survival and cell-cycle control or effects on DNA 
repair. The molecular mechanisms of these interactions remain unresolved.
3.2 p53 and DNA repair in cytoplasm
Under normal conditions a basal pool of p53 is retained intra-cellular, with the 
distribution of p53 between the different subcellular compartments dependent 
on the cellular stress milieu [28]. Indeed, wtp53 occurs in cytoplasm in a subset 
of human tumor cells such as breast cancers, colon cancers and neuroblastoma 
[73–75]. Shuttling between nucleus and cytoplasm not only regulates protein 
localization, but also often impacts on protein function.
p53, localized in the cytoplasmic lysates of non-stressed p53-proficient cell 
lines [e.g. LCC2, HCT116 (p53+/+)] exerts an inherent 3′ → 5′ exonuclease activity 
displaying identical biochemical functions characteristic for recombinant wtp53 
[76, 77]: 1) it removes 3′-terminal nucleotides from various nucleic acid substrates: 
ssDNA, dsDNA, and RNA/DNA template-primers, 2) it hydrolyzes ssDNA in 
preference to dsDNA substrate, 3) it shows a marked preference for excision of 
a mismatched vs. correctly paired 3′ terminus with RNA/DNA and DNA/DNA 
substrates, 4) it excises nucleotides from nucleic acid substrates independently 
from DNA polymerase, 6) it fulfills the requirements for proofreading function; 
acts coordinately with the exonuclease-deficient viral DNA polymerases.
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Viruses exploits their cellular host for their successful replication, they utilize 
cell proteins for multiple purposes during their intracellular replication [78]. Since 
viral infection evokes cellular stress, the infected cells harbor stabilized activated 
p53 and manipulate p53’s guardian role. Interestingly, increased p53 levels have been 
noted following infection of cells with various viruses including retrovirus-human 
immunodeficiency virus [79], which exhibits exceptionally high genetic variability 
[6], due to the low fidelity of the replication apparatus that is exclusive to the 
retroviral life cycle.
Reverse transcriptase (RT) of HIV-1 is responsible for the conversion of the viral 
genomic ssRNA into the proviral DNA in the cytoplasm [7]. The lack of intrinsic 
3′ → 5′ exonuclease activity, the formation of 3′-mispaired DNA and the subsequent 
extension of this DNA were shown to be determinants for the low fidelity of HIV-1 
RT [80]. p53 can proofread for HIV-1 RT, increasing the fidelity of DNA synthesis 
by excising incorrectly polymerized nucleotides from RNA/DNA and DNA/DNA 
temple-primers in the direct exonuclease assay, when first binding to a 3′-terminus 
and during ongoing DNA synthesis in vitro with both template-primers [76]. The 
role of p53 in proofreading is two-fold: to excise preexisting 3′-terminal mismatches 
and to prevent the extension of 3′-mismatched primer ends by the polymerase [76]. 
p53 with its inherent exoribonuclease activity and excision of mispairs, has a poten-
tial to serve as an external trans-acting proofreader, providing the host-derived 
repair mechanism in cytoplasm.
3.3 p53 and DNA repair in mitochondria
DNA polymerase (pol) γ is the sole DNA polymerase that is responsible for 
replication and repair of mtDNA [81]. It is well established that defects in mtDNA 
replication lead to mitochondrial dysfunction and disease [56, 60]. Mutations in 
mtDNA can arise from exogenous sources, from endogenous oxidative stress, or as 
spontaneous errors of replication during either DNA synthesis or repair events [82]. 
Mitochondrial DNA is replicated by DNA polymerase γ in concert with replisome 
accessory proteins such as the mitochondrial DNA helicase, single-stranded DNA 
binding protein, topoisomerase, the multifunctional mitochondrial transcription 
factor A (TFAM) with important roles in mtDNA replication and initiating factors.
A high frequency of mutations within mtDNA, resulting in mitochondrial 
dysfunctions, is an important source of various diseases including cancer and 
human aging [81, 82]. To verify mtDNA integrity, cells hold various DNA damage 
response pathway(s) comprising mtDNA replication/repair preservation programs 
that either preclude or repair damage [83]. The mutagenic mechanisms were shown 
to be replication errors formed by either pol γ during DNA synthesis by incorpora-
tion of incorrect nucleotide or produced due to the presence of unbalanced dNTP 
concentrations, or by diminished proofreading efficiency. MtDNA is not protected 
by histones and mtDNA repair is ineffective [81]. Furthermore, a potentially impor-
tant source of replication infidelity is damage due to ROS. pol γ, was demonstrated 
to stably misincorporate highly mutagenic 8-oxo-7,8-dihydro-2′-deoxyguanosine 
(8-oxodG) opposite template adenine in a complete DNA synthesis reaction in 
vitro [84].
Because of the susceptibility of mtDNA to oxidative damage and replica-
tion errors, it is vital to protect mtDNA genomic stability to preserve health. 
Mitochondrial localization of p53 was observed in non-stressed and stressed cells 
[26]. Mitochondrial p53 (mit-p53) levels are proportional to total p53 levels, and the 
majority of p53 was present inside the intra-mitochondrial compartment-matrix, 
in which mtDNA is located [85]. The mit-p53 physically and functionally interacts 
with both, mtDNA and pol γ [86].
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Notably, with the exception of NER, components of these nuclear DNA repair 
pathways are also shared in mtDNA maintenance. Several studies illustrated the 
participation of p53 in mtDNA repair:
a. 53 enhances mitochondrial BER (mtBER) through direct interaction with the 
repair complex in mouse liver and cancer cells [87]. p53 modulates mtBER 
through the stimulation of the nucleotide incorporation step.
b. p53 interacts physically with human mtSSB (HmtSSB) in vitro via its transac-
tivation domain and is proficient of hydrolyzing the 8-oxodG present at the 
3′-end of DNA, a well-known marker of oxidative stress [88].
c. Intra-mitochondrial p53 provides an error-repair proofreading function for 
pol γ by excision of misincorporated nucleotides [89]. The p53 in mitochondria 
may affect the accuracy of DNA synthesis by acting as an external proofreader, 
thus reducing the production of polymerization errors.
4. Removal of nucleoside analogs from DNA by p53 protein.
In addition to having a critical role in preservation of genome integrity, altera-
tions in the expression, and function of DNA repair proteins are a major facilitator 
of tumor responses to chemo- and radiotherapy, commonly functioning by inducing 
DNA damage in tumor cells. Nucleoside analogs, clinically active in cancer chemo-
therapy (e.g. Ara-C, in the treatment of hematological malignancies, or gemcitabine-
dFdC, against a variety of solid tumors) and in treatment of virus infections (e.g. 
3′-azido-2,3,-deoxythymidine-AZT, inhibitors of HIV-1 RT), are incorporated into 
DNA and cause cell death or inhibition of viral replication [90, 91]. These drugs are 
intracellularly converted to the active analog triphosphates, compete with physiolog-
ical nucleosides and are then inserted into replicating DNA. The incorporated NA, 
structurally mimicking a mismatched nucleotide at the 3′-terminus, blocks further 
extension of the nascent strand (chain termination) and causes stalling of replica-
tion forks with higher probability to the dissociation of the enzyme from template-
primer [91]. Furthermore, the high toxicity of NA compounds may be caused by 
high rates of incorporation of the NA into DNA and their persistence in DNA due 
to inefficient excision. Removal of drugs by 3′ → 5′ exonuclease activity intrinsic 
to DNA polymerase or by external proofreading activity of external polymerases 
or proteins is presumably a potential cellular mechanism of resistance to anti-viral 
drugs or anti-cancer drugs.
The cytotoxic activity of gemcitabine (2′2’-difluorodeoxycitidine, dFdC) was 
strongly correlated with the amount of dFdCMP incorporated into cellular DNA 
[92]. The p53 protein recognizes dFdCMP-DNA in whole cells, as evidenced by the 
fact that p53 protein rapidly accumulated in the nuclei of the gemcitabine treated 
ML-1 cells [93]. Although, the excision of the dFdCMP from the 3′-end of the 
DNA was slower than the excision of mismatched nucleotides in whole cells with 
wtp53 (ML-1) and not detectable in CEM cells harboring mutant p53. ML-1 cells 
were more sensitive to the cytotoxic effect of the drugs compared to the p53-null 
or mutant cells. The recognition of the incorporated NAs in DNA by wtp53 did not 
confer resistance to gemcitabine, but may have facilitated the apoptotic cell death 
process. It was reported that treatment with gemcitabine resulted in an increased 
production of DNA-dependent protein kinase (DNA-PK) and p53 complex in 
nucleus, that interacts with the gemcitabine-containing DNA [93, 94]. DNA-PK 
and p53 sensor complex may serve as a mechanism to activate the pro-apoptosis 
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function of p53. Apparently, the prolonged existence of the NA-stalled DNA end 
induced the kinase activity, which subsequently phosphorylated p53 and activated 
the downstream pathways leading to apoptosis.
Remarkably, p53 present in complex with DNA-PK exhibited 3′ → 5′ exonuclease 
activity with mismatched DNA, however the active p53 was unable of excising 
efficiently the incorporated drug from NA-DNA construct containing gemcitabine 
at the 3′-end [94]. Notably, the specific effects of gemcitabine exposure appeared to 
vary depending on the duration of treatment and upon the cell line.
It should be pointed out, that wtp53 in ML-1 cells removed the purine nucleoside 
analog fludarabine (F-ara-A) more efficiently than gemcitabine [93]. Further stud-
ies are needed to assess the role of p53 in cellular response to various anti-cancer 
purine and pyrimidine NA-induced DNA damage.
HIV-1 RT readily utilizes many NAs and the incorporation of nucleoside RT 
inhibitors (NRTIs) into the 3′-end of viral DNA leads to chain termination of viral 
DNA synthesis in cytoplasm [88, 95]. p53 protein in the cytoplasm excises the 
incorporated NAs during both RNA-dependent and DNA-dependent DNA polym-
erization reactions, although less efficiently than the mismatched nucleotides; 
longer incubation times were required for excision of the terminally incorporated 
analogs [96]. The data suggest that p53 in cytoplasm may act as an external 
proofreader for NA incorporation and confer cellular resistance mechanism to the 
anti-viral compounds.
Pol γ is unique among the cellular replicative DNA polymerases as it is sensitive 
to inhibition by nucleoside analogue reverse transcriptase inhibitors (NRTIs) used 
in the treatment of HIV, which can cause an induced mitochondrial toxicity [97]. 
Acquired mitochondrial toxicity occurs as a consequence of incorporation of NA 
into mtDNA or inhibition of mtDNA replication or both. A terminally incorporated 
NA may be removed by p53 in mitochondria [97]. The removal of the incorporated 
NA by p53 exonuclease, indicates that the presence of the cellular component-p53 
in mitochondria may be important in defining the cytotoxicity of NAs toward 
mitochondrial replication, thus affecting risk–benefit approach (NA toxicity versus 
viral inhibition) [98, 99]. Apparently, the presence of p53 in mitochondria may 
be important, as the excision of the mispair and NA by p53 is favorable event for 
mitochondrial function.
p53 is a multifunctional protein with positive and negative effects. In general, 
drug resistance that occurs in cancer chemotherapy and antiviral therapy is a 
negative event that will decrease the efficacy of the treatment. The recognition and 
removal of NA from drug-containing DNAs by p53 exonuclease activity in various 
compartments of the cell may play a role in decreasing drug activity, leading to 
various biological outcomes: 1)the excision of the incorporated NA from DNA in 
nucleus may confer resistance to the drugs (negative effect) [93]; 2)the removal of 
the NA by p53 from DNA incorporated by HIV-1 RT in cytoplasm may confer resis-
tance to the drugs by non-viral mechanism (negative effect) [96] and 3)the excision 
of NAs from mitochondrial DNA may decrease the potential for chain termination 
and host toxicity (positive effect) [97].
5. Excision of non-canonical nucleotides by p53 protein
The genome is constantly under attack from extrinsic and intrinsic damaging 
agents. Uracil (dU) mis-incorporation in DNA is an intrinsic factor resulting in 
genomic instability and DNA mutations. The excessive levels of genomic uracil 
in DNA can modify gene expression by interfering with promoter binding and 
transcription inhibition, can change transcriptional stalling, or induce DNA strand 
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breaks leading to apoptosis. The factors that influence uracil levels in DNA are 
cytosine deamination, de novo thymidylate (dTMP) biosynthesis, salvage dTMP 
biosynthesis, and DNA repair. Furthermore, mis-incorporation occurs when DNA 
polymerases incorporate dUTP into DNA, in place of dTTP, and the rate of mis-
incorporation is believed to be determined by the intracellular dUTP:dTTP ratio 
[100, 101]. The enzyme deoxyuridine triphosphate nucleotidohydrolase (dUTPase), 
which facilitates the conversion of dUTP to dUMP further utilized by thymidylate 
synthase (TS) for synthesis of dTMP, avoids mis-incorporation of dU into DNA in 
nucleus by decreasing the dUTP/dTTP ratio [101]. The misincorporation of dU, as 
a result of accumulation of dUTP, plays a critical role in cytotoxicity mediated by 
TS inhibitors, such as the commonly used anticancer drug 5-fluorouracil (5-FU) 
[102]. DNA directed cytotoxicity of chemotherapeutic agents (e.g.5-FU) not only 
depends on accumulation of dUTP, but may also be determined by the efficiency of 
the DNA repair mechanisms (e.g. excision repair) which preclude the incidence of 
the mistake.
Pol γ in mitochondria is incapable to readily correct U:A mismatches [11]. HIV-1 
RT in the cytoplasm of HIV-infected cells efficiently inserts the non-canonical 
dUTP into the proviral DNA and extends the dU-terminated DNA [103]. The 
misincorporation of dUTP leads to mutagenesis, and to down-regulation of viral 
gene expression [104].
Within the context of error-correction events, p53 as a DNA binding protein, 
contributes an external proofreading function; upon excision of the dU, the p53 
dissociates, thus letting the transfer of the substrate with the correct 3′-terminus to 
DNA polymerase and renewal of DNA synthesis.
The biochemical data show that the procession of U:A and mismatched U:G 
lesions enhances in the presence of recombinant or endogenous cytoplasmic or 
mitochondrial p53 [105]. p53 in cytoplasm can participate through the intermolecu-
lar pathway in a dU-damage-associated repair mechanism by its ability to remove 
preformed 3′-terminal dUs, thus preventing further extension of 3’ dU-terminated 
primer during DNA synthesis by HIV-1 RT. Similarly, p53 in mitochondria can func-
tion as an exonuclease/proofreader for pol γ by either decreasing the incorporation 
of non-canonical dUTP into DNA or by promoting the excision of incorporated dU 
from nascent DNA, thus expanding the spectrum of DNA damage sites exploited 
for proofreading as a trans-acting protein [106].
During genomic DNA replication another form of replication errors arises 
during the incorporation of nucleotides carrying the correct base, but the wrong 
sugar at substantial rates [107]. DNA polymerases often incorporate ribonucleoside 
triphosphates (rNTPs) into DNA because of the much higher concentration of 
rNTPs than that of dNTPs in the cellular nucleotide pool. Indeed, more than 106 
rNMPs are incorporated during one round of replication of a mammalian genome 
[107]. Newly incorporated rNMPs destabilize DNA and pose a major threat to 
genome integrity due to their reactive 2’OH group. The inserted rNs are the most 
abundant non-canonical nucleotides in the genome. Failure of rN removal is 
associated with genome instability in the form of mutagenesis, replication stress, 
DNA breaks, and chromosomal rearrangements. The aberrant accumulation of 
rNs in the genome leads to human diseases including Aicardi–Goutières syndrome 
(AGS), the severe autoimmune disease, and tumorigenesis [108]. Mammalian cells 
have developed strategies to prevent persistent rN accumulation. In eukaryotes, rNs 
embedded into DNA are primarily repaired by RNase H2-initiated repair pathway. 
Ribonucleotide excision repair (RER) may be directly coupled to replication and 
results in rapid post-replicative repair of rNMPs [108]. Remarkably, exonuclease-
proficient yeast and human DNA polymerases can proofread incorporated rNs, 
albeit inefficiently [107].
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Recent studies have demonstrated the importance of p53 in 3′-terminal RER 
pathway through a functional collaboration with HIV-1 RT, acting in a coordinated 
manner to attain higher fidelity. p53, functioning as a trans-acting proofreader 
in cytoplasm, can decrease the stable incorporation of rNs, into DNA by HIV-1 
RT [109]. p53 can influence events needed for RER by possessing the compatible 
biochemical properties: p53 is pertinent in the correction of replication errors pro-
duced by HIV-1 RT during distinct steps of rN incorporation through intermolecu-
lar pathway: by removal pre-existing 3′-terminal rN; by reducing rN incorporation; 
by preventing extension of a 3′ rN-terminated primer, by attenuating stable incor-
poration of rNs. Thus, p53, functioning as a trans-acting proofreader in cytoplasm, 
can decrease the stable incorporation of rNs.
The fact that p53 in cytoplasm can edit an incorrect sugar irrespective of the 
nature of base, expands the role of p53 as a proofreader in the repair of replication 
errors by removing both a base mismatch and an incorrect sugar.
6. Conclusions
Mammalian cells have evolved multiple strategies to safeguard the genetic 
information to prevent the fixation of genetic damage induced by endogenous 
and exogenous mutagens [16]. p53 protein plays a crucial role in the regulation 
of cell fate determination in response to a variety of cellular stresses. p53 may 
exert the functional heterogeneity in its non-induced and in its activated state 
[16]. Remarkably, DNA repair transcription-independent functions of wtp53, 
contributing to tumor suppression, were found to protect cells from DNA damage 
independently of the transcription-mediated functions of p53 [25]. Thus, a more 
comprehensive understanding of how p53 transcription- independent functions 
are induced in response to a variety of cellular insults is vital. This report focuses on 
direct roles of p53 in DNA repair during DNA replication in various compartments 
of the cell. Apparently, p53 has more than one contributions to DNA replication 
fidelity, which could depend on sub-cellular localization of p53, on the type and 
incidence of replication obstacles, on the levels of p53 protein [28].
p53 is able to elicit a spectrum of different effective DNA repair pathways in 
nucleus, cytoplasm and mitochondria (Figure 4). Within the nucleus, p53 regulates 
different repair mechanisms, in response to endogenous and exogenous replica-
tive stress: e.g. HR (by restricting excess recombination through interactions with 
Rad51), NER, BER, and MMR through interactions with relevant components of 
the respective pathways [25, 31].
In the cytoplasm, p53 may contribute effective proofreading for exonuclease-
deficient DNA polymerases (e.g.HIV-1 RT) thereby correcting errors produced 
during DNA replication [110, 111]. Moreover, the proofreading activity of p53 may 
limit the transversion mutations, indicating that p53 may affect the mutation spec-
tra of DNA polymerase by acting as an external proofreader [111]. Recent studies 
also show that cytoplasmic p53 possesses the potential to remove the incorporated 
non-canonical dUTP into DNA by HIV-1 RT through an intermolecular pathway 
[105]. Furthermore, p53, functioning as a trans-acting proofreader, can decrease 
the stable incorporation of rNs [109]. The data implies that p53 excises incorrect 
sugar in addition to base mispairs, thereby expanding the role of p53 in the repair of 
replication errors.
Within the mitochondria, various studies illustrated the participation of p53 
in mtDNA repair in a variety of systems: a)p53 enhances BER through direct 
interaction with the repair complex in mouse liver and cancer cells [87]. b) Intra-
mitochondrial p53 provides an error-repair proofreading function for pol γ by 
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excision of misincorporated nucleotides [89]. c)p53 is proficient of hydrolyzing the 
8-oxo-7,8-dihydro-2′-deoxy-guanosine (8-oxodG) present at the 3′-end of DNA, a 
well-known marker of oxidative stress [88]. d)p53 regulates mtDNA copy number, 
which may impact mitochondrial and cellular functions [112].
Therapeutic strategies based on p53 are particularly interesting because they 
exploit the cancer cell’s intrinsic genome instability and predisposition to cell 
death-apoptosis [90, 91]. The role of p53 is predominantly relevant with respect to 
the development of anticancer and antiviral therapies. Removal of drugs by 3′ → 5′ 
exonuclease activity may also facilitate resistance to anti-cancer or anti-viral treat-
ments. Clinical drug resistance limits the efficacy of these compounds. Uncovering 
the mechanisms, which are responsible for DNA repair of NA-induced DNA 
damage will have therapeutic value. The p53 protein is able to remove incorporated 
NA. The stress induced activation of p53 that occurs during anti-cancer or anti-viral 
therapy has negative and positive effects. p53 may remove incorporated therapeutic 
NAs from DNA or trigger apoptosis. More studies regarding functions of p53 in 
genome integrity and cancer evolution may facilitate drug screening and better 
design of therapeutic approaches.
7. Future directions
The functional interaction between p53 and DNA polymerase may have impor-
tant consequences for the maintenance of genomic integrity and in the development 
Figure 4. 
p53 functions in DNA repair. p53 under both normal and stress conditions, can help cellular and viral DNA 
polymerases to promote the repair of DNA in various cellular compartments. The result of p53 activation 
depends on many variables, including the extent of the stress or damage. In this model, basal p53 activity or 
that induced by stress signals elicits the protector responses that support the repair of genotoxic damage by 
various pathways.
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of p53- targeted clinical therapies. Further assessments are required to establish the 
role of p53 in DNA replication and the significance of these functions in various 
cellular compartments and treatment responses. Studies on the biology of various 
mutant p53 isoforms and their interaction with the factors involved in DNA repair 
and apoptosis, will be relevant to establish whether the direct involvement of p53 
in DNA repair is a tumor suppressor function of this important anti-oncogene. 
Characterization of exonuclease-deficient H115N mutant p53 revealed that 
although exonuclease-mutant H115N p53 can induce cell cycle arrest more effi-
ciently than wild-type p53, its ability to produce apoptosis in DNA damaged cells is 
markedly impaired [113]. By utilizing various function-mutant p53 isoforms, more 
studies must be conducted on the biology of mutant p53 forms and their interaction 
with the factors involved in DNA repair and apoptosis, in order to recognize the 
molecular mechanisms that mediate p53-dependent control of DNA replication by 
cellular and viral DNA polymerases.
p53 has a dual role in response to therapy, as exonuclease that by excision of 
incorporated anti-cancer drugs may confer resistance to drugs or as mediator of 
cell death induced by chemotherapy [93]. p53, by removal of the incorporated NA, 
could confer a cellular resistance mechanism to the antiviral compounds. Finally, 
the excision of NAs from mitochondrial DNA may decrease the potential for chain 
termination and host toxicity. These features could serve as a template for the 
development of p53-targeting therapies.
The control of the viral mutation rate could be a practical anti-retroviral strat-
egy. The mutagenic capacity of a low fidelity DNA polymerase will be decreased 
through increase in exonuclease concentration or exonuclease targeting (increase in 
local p53 concentration). It is important to further elucidate the molecular mecha-
nisms involved in governing fidelity not only at a molecular level (i.e., intrinsic RT 
fidelity), but also related to the cytoplasmic p53 protein that can control the viral 
mutation rate and can affect the incorporation of NAs into viral DNA. New under-
standings of the sub-cellular localization of p53, its role in the fidelity of proviral 
DNA synthesis in cytoplasm and drug resistance, may create the basis for new 
strategies in targeted antiviral therapy that focus on the sub-cellular context of p53 
in cells.
A major issue in the future would be to characterize the cellular and biological 
functions of p53 in mitochondria in response to various stresses. There are many 
missing links about the biological functions of mitochondrial p53 that are required 
to be investigated. Whether p53 defines the percent of mutated mtDNA (hetero-
plasmy in a cell)? Uncovering the mechanisms by which pol γ-mediated mtDNA 
mutations and depletion are manifested in cells in the absence and presence of p53 
is significant step in understanding underlying causes for mtDNA–related diseases. 
Depletion and mutation of mtDNA may lead to cellular respiratory dysfunction and 
release of reactive oxidative species, resulting in cellular damage [99]. Future NAs 
should provide higher specificity for HIV-RT and lower incorporation by pol γ to 
diminish mitochondrial toxicity. Whether the effective targeting of p53 in mito-
chondria by error-correction functions, may result in decrease of mitochondrial 
toxicity in response to conventional anti-viral therapies? Understanding how p53 
can be imported into mitochondria, will be important and could contribute toward 
the design of new therapies for various diseases.




1 Infectious Diseases Unit, Sheba Medical Center, Tel-Hashomer, Israel
2 The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 
Ramat-Gan, Israel
*Address all correspondence to: bakhanus@yahoo.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
19
The Role p53 Protein in DNA Repair
DOI: http://dx.doi.org/10.5772/intechopen.99051
References
[1] Kunkel TA, Bebenek K. (2000) DNA 
replication fidelity. Ann. Rev. Biochem. 
69: 497-529.
[2] Lan-Ya Li, Yi-di Guan , Xi-Sha Chen, 
Jin-Ming Yang , Yan Cheng. (2021) DNA 
repair pathways in cancer therapy and 
resistance. Front Pharmacol. 11: 629266.
[3] D'Amico AM, Vasquez KM. (2021) 
The multifaceted roles of DNA repair 
and replication proteins in aging and 
obesity. DNA Repair 99:103049.
[4] Rahimian E, Amini A, Alikarami F, 
Pezeshki SMS, Saki N, Safa M. (2020) 
DNA repair pathways as guardians of 
the genome: Therapeutic potential and 
possible role in hematologic neoplasms. 
DNA repair 96:102951.
[5] Jackson AL, Loeb LA. (1998) The 
mutation rate and cancer. Genetics 148: 
1483-1490.
[6] Katz R, Skalka AM. (1990) 
Generation of diversity in retroviruses. 
Ann. Rev. Genet. 24: 409-445.
[7] Svarovskaya ES, Cheslock SR, 
Zhang W, Hu W, Pathak VK (2003) 
Retroviral mutation rates and reverse 
transcriptase fidelity. Front. Biosci.8: 
d117-d134.
[8] Menéndez-Arias L. (2009) Mutation 
rates and intrinsic fidelity of retroviral 
reverse transcriptases. Viruses. 1: 
1137-1165.
[9] Trimpert J, Groenke N, Kunec D, 
Eschke K, He S, McMahon DP, 
Osterrieder N. (2019) A proofreading- 
impaired herpersvirus generates 
populations with quasispecies-like 
structure. Nat. Microbiology 4:2175-2183.
[10] Copeland WC, Ponamarev MV, 
Nguyen D, Kunkel TA, Longley MJ. 
(2003) Mutations in DNA polymerase 
gamma cause error-prone DNA 
synthesis in human disorders. Acta 
Biochim Pol. 50:155-167.
[11] Kaguni LS. (2004) DNA polymerase 
γ, the mitochondrial replicase. Ann. Rev. 
Biochem.73:293-320
[12] Singh KK. (2004) Mitochondria 
damage checkpoint in apoptosis and 
genome stability. FEMS Yeast Res.5: 
127-132.
[13] Pesole G, Gissi C, De Chirico A, 
Saccone C. (1999) Nucleotide 
substitution rate of mammalian 
mitochondrial genomes. J Mol Evol 48: 
427-434.
[14] Johnson A, Johnson K. (2001a) 
Fidelity of nucleotide incorporation by 
human mitochondrial DNA polymerase. 
J Biol. Chem. 276: 38090-38106.
[15] Johnson A, Johnson K. (2001b) 
Exonuclease proofreading by human 
mitochondrial DNA polymerase. J Biol. 
Chem. 276: 38097-38107.
[16] Zhang H. (2020) Mechanisms of 
mutagenesis induced by DNA lesions: 
multiple factors affect mutations in 
translesion DNA synthesis. Crit Rev 
Biochem. Mol Biol. 55:219-251.
[17] Reha-Krantz. (2010) DNA 
polymerase proofreading: Multiple roles 
maintain genome stability. BBA 1804: 
1049-1063.
[18] McElhinny SAN, Pavlov Y, Kunkel T. 
(2006) Evidence for extrinsic 
exonucleolytic proofreading. Cell Cycle 
5: 958-962.
[19] Levine AJ, Oren M. (2009) The first 
30 years of p53: growing ever more 
complex. Nat Rev Cancer. 9:749-758.
[20] Vousden KH, Prives C (2009) 
Blinded by the light: The growing 
complexity of p53. Cell 137: 413-431.
P53 - A Guardian of the Genome and Beyond
20
[21] Soussi T (1995) The p53 tumor 
suppressor gene: From molecular 
biology to clinical investigation. In 
Molecular Genetics of Cancer (Cowell, 
J.K., ed.), p135-178, Bios. Scientific, 
Oxford, UK.
[22] Freed-Pastor WA, Prives C. (2012) 
Mutant p53: One name, many proteins. 
Genes. Dev. 26: 1268-1286.
[23] Levine AJ. Levine AJ. (2020) 
p53:800 million years of evolution and 
40 years of discovery. Nat Rev 
Cancer.20: 471-480
[24] Taira N, Yoshoda K. (2012) Post-
translational modifications of p53 tumor 
suppressor:Determinants of its 
functional targets. Histol Histopathol. 
27: 437-443.
[25] Ho T, Tan BX, Lane D. (2019) How 
the other half lives: What p53 does when 
it is not being a transcription Factor. Int 
J Mol Sci. 21: 13.
[26] Marchenko ND, Zaika A, Moll UM. 
(2000) Death signal-induced 
localization of p53 protein to 
mitochondria. A potential role in 
apoptotic signaling. J. Biol. Chem. 275: 
16202-16212.
[27] Zhou J, Ahn J, Wilson SH, Prives C. 
(2001) A role for p53 in base excision 
repair. EMBO J. 20: 914-923.
[28] Janus F, Albrechtsen N, 
Knippschild U, Wiesmuller L, Grosse F, 
Deppert W. (1999) Different regulation 
of the p53 core domain activities 3′ to 5′ 
exonuclease and sequence-specific DNA 
binding. Mol. Cell. Biol. 19: 2155-2168.
[29] Offer H, Wolkowicz R, Matas D, 
Blumenstein S, Livneh Z, Rotter V. 
(1999) Direct involvement of p53 in the 
base excision repair pathway of the 
DNA repair machinery. FEBS Lett. 450: 
197-204.
[30] Albrechtsen N, Dornreiter L, 
Grosse F, Kim E, Wiesmuller L, Deppert 
W (1999) Maintenance of genomic 
integrity by p53: Complementary roles 
for activated and non-activated p53. 
Oncogene 18: 7706-7717.
[31] Gatz SA, Wiesmüller L. (2006) p53 
in recombination and repair. Cell Death 
Differ;13:1003-1016.
[32] Gottifredi V, Wiesmüller L. (2018) 
The tip of an iceberg: Replication-
associated functions of the tumor 
suppressor p53. Cancers 10: 250
[33] Kern SE, Kinzler KW, Baker SJ, 
Nigro JM, Rotter V, Levine AJ, 
Friedman P, Prives C. Vogelstein B. 
(1991) Mutant p53 binds DNA 
abnormally. Oncogene 6: 131-136.
[34] Steinmeyer K, Deppert W. (1988) 
DNA binding properties of murine p53. 
Oncogene 3: 501-507.
[35] Bakalkin G, Yakovleva T, 
Selivanova G, Magnusson KP, Szekely L, 
Kiseleva E, Klein G, Terenius L, 
Wiman KG. (1994) p53 binds single-
stranded DNA ends and catalyzes DNA 
renaturation and strand transfer. Proc. 
Natl. Acad. Sci. USA 91: 413-417.
[36] Oberosler P, Hloch P, 
Rammsperger U, Stahl H. (1993) 
p53-catalyzed annealing of 
complementary single-stranded nucleic 
acids. EMBO J 12: 2389-2396.
[37] Lee S, Elenbaas B, Levine A, Griffith 
J (1995) p53 and its 14kDa C-terminal 
domain recognize primary DNA damage 
in the form of insertion/deletion 
mismatches. Cell 81: 1013-1020.
[38] Dudenhoffer C, Rohaly G, Will K, 
Deppert W, Wiesmullar L.(1998) 
Specific mismatch recognition in 
heteroduplex intermediates by p53 
suggests a role in fidelity control of 
homologous recombination. Mol.Cell.
Biol. 18: 5332-5342.
[39] Hwang BJ, Ford J.M, Hanawalt PC, 
Chu G. (1999) Expression of the p48 
21
The Role p53 Protein in DNA Repair
DOI: http://dx.doi.org/10.5772/intechopen.99051
xeroderma pigmentosum gene is 
p53-dependent and is involved in global 
genomic repair. Proc.Natl. Acad. Sci. 
USA, 96: 424-428.
[40] Mummenbrauer T, Janus F, 
Muller B, Wiesmuller L, Deppert W, 
Gross F. (1996) p53 protein exhibits 
3′→5′ exonuclease activity. Cell 85: 
1089-1099.
[41] Huang P. (1998) Excision of 
mismatched nucleotides from DNA: A 
potential mechanism for enhancing 
DNA replication fidelity by the wild-
type p53 protein. Oncogene 17: 261-270.
[42] Skalski V, Lin Z, Choi BY, 
Brown KR. (2000) Substrate specificity 
of the p53-associated 3′→5′ exonuclease. 
Oncogene 19: 3321-3329.
[43] Bakhanashvili M. (2001) 
Exonucleolytic proofreading by p53 
protein. Eur.J Biochem. 268: 2047-2054.
[44] Offer H, Milyavsky M, Erez N, 
Matus D, Zurer I, Harris CC, Rotter V. 
(2001) Structural and functional 
involvement of p53 in BER in vitro and 
in vivo. Oncogene 20: 581-589.
[45] Gaiddon C, Moorthy NC, Prives C. 
(1999) Ref-1 regulates the 
transactivation and proapoptotic 
functions of p53 in vivo. EMBO J. 18: 
5609-5621.
[46] Williams, AB, Schumacher B. 
(2016) p53 in the DNA-damage-repair 
process. Cold Spring Harb. Perspect. 
Med. 6, a026070.
[47] Rubbi C.P, Milner J. (2003) p53 is a 
chromatin accessibility factor for 
nucleotide excision repair of DNA 
damage. EMBO J. 22, 975-986.
[48] Wang XW, Yeh H, Schaeffer L, 
Roy R, Moncollin V, Egly JM, Wang Z, 
Taffe BG, et al. (1995) p53 modulation 
of TFIIH-associated nucleotide excision 
repair activity. Nat. Genet. 10: 188-195.
[49] Scherer SJ, Maier SM, Seifert M, 
Hanselmann RG, Zang KD, 
Muller-Hermelink HK, Angel P, 
Welter C, Schartl M. (2000) p53 and 
c-Jun functionally synergize in the 
regulation of the DNA repair gene 
hMSH2 in response to UV. J. Biol. Chem. 
275, 37469-37473.
[50] Subramanian D, Griffth JD.(2002) 
Interactions between p53, hMSH2-
hMSH6 and HMG I(Y) on 
Hollidayjunctions and bulged bases. 
Nucleic Acids Res. 30, 2427-2434.
[51] Subramanian D, Griffth JD. (2005) 
Modulation of p53 binding to Holliday 
junctions and 3′-cytosine bulges by 
phosphorylation events. Biochemistry 
44, 2536-2544.
[52] Cranston A, Bocker T, Reitmair A, 
Palazzo J, Wilson T, Mak T, Fishel R. 
(1997) Female embryonic lethality in 
mice nullizygous for both Msh2 and p53. 
Nat Genet. 17:114-118.
[53] Pabla N, Ma Z, McIlhatton MA, 
Fishel R, Dong Z. (2011) hMSH2 
recruits ATR to DNA damage sites for 
activation during DNA damage-induced 
apoptosis. J Biol Chem. 286:10411- 
10418.
[54] Shevelev IV, Hubscher U. (2002) 
The 3′→5′ exonucleases. Nat.Rev. 
3: 1-12.
[55] Perrino FW, Preston BD, Sandell LL, 
Loeb LA. (1989) Extension of 
mismatched 3’termini of DNA is a major 
determinant of the infidelity of human 
immunodeficiency virus type 1 reverse 
transcriptase. Proc. Natl. Acad. Sci. USA 
86: 8343-8347.
[56] Kunkel TA. (2004) DNA replication 
fidelity. J Biol. Chem. 279: 16895-16898.
[57] Bebenek K, Roberts JD, Kunkel TA. 
(1992) The effects of dNTP pool 
imbalances on frameshift fidelity during 
DNA replication. J Biol Chem.;267: 
3589-3596.
P53 - A Guardian of the Genome and Beyond
22
[58] Boyer JC, Thomas DC, Maher VM, 
McCormick JJ, Kunkel TA. (1993) 
Fidelity of DNA replication by extracts 
of normal and malignantly transformed 
human cells. Cancer Res. 53: 3270-3275.
[59] Hurwitz J, Dean FB, Kwong AD, 
Lee SH. (1990) The in vitro replication 
of DNA containing the SV40 origin. J 
Biol Chem. 265:18043-18046.
[60] McCulloch SD, Kunkel TA. (2008) 
The fidelity of DNA synthesis by 
eukaryotic replicative and translesion 
synthesis polymerases. Cell Res. 18: 
148-161.
[61] Cox LS, Hupp T, Midgley CA, Lane 
DP (1995) A direct effect of activated 
human p53 on DNA replication. EMBO J 
14: 2099-2105.
[62] Ballal K, Zhang W, Mukhopadyay T, 
Huang P. (2002) Suppression of 
mismatched mutation by p53: A 
mechanism guarding genomic integrity. 
J. Mol. Med. 80: 25-32.
[63] Melle C, Nasheuer H. (2002) 
Physical and functional interactions of 
the tumor suppressor protein p53 and 
DNA polymerase α-primase. Nucleic 
Acids Res. 30: 1493-1499.
[64] Bertrand P, Saintigny Y, Lopez BS. 
(2004) p530s double life: 
Transactivation-independent repression 
of homologous recombination. Trends 
Genet. 20, 235-243.
[65] Romanova LY, Willers H, 
Blagosklonny MV, Powell SN. (2004) 
The interaction of p53 with replication 
protein a mediates suppression of 
homologous recombination. Oncogene 
23: 9025-9033.
[66] Rieckmann T, Kriegs M, Nitsch L, 
Hoffer, K, Rohaly G, Kocher S, 
Petersen C, Dikomey E, Dornreiter I, 
Dahm-Daphi J. (2013) p53 modulates 
homologous recombination at I-SceI-
induced double-strand breaks through 
cell-cycle regulation. Oncogene 
32: 968-975
[67] Janz C, Wiesmuller L. (2002) 
Wild-type p53 inhibits replication-
associated homologous recombination. 
Oncogene 21: 5929-5933
[68] Linke SP, Sengupta S, Khabie N, 
Jeffries BA, Buchhop S, Miska S, et al. 
(2003) p53 interacts with hRAD51 and 
hRAD54, and directly modulates 
homologous recombination. Cancer Res. 
63: 2596-2605.
[69] Yang T, Namba H, Hara T, 
Takmura N, Nagayama Y, Fukata S, 
Ishikawa N, Kuma K, Ito,.K, 
Yamashita S. (1997) p53 induced by 
ionizing radiation mediates DNA 
end-jointing activity, but not apoptosis 
of thyroid cells. Oncogene 14:  
1511-1519.
[70] Tang W, Willers H, Powell SN. 
(1999) p53 directly enhances rejoining 
of DNA double-strand breaks with 
cohesive ends in gamma-irradiated 
mouse fibroblasts. Cancer Res. 59: 
2562-2565.
[71] Akyuz N, Boehden GS, Susse S, 
Rimek A, Preuss U, Scheidtmann KH, 
Wiesmuller L. (2002) DNA substrate 
dependence of p53-mediated regulation 
of double-strand break repair. Mol. Cell. 
Biol. 22: 6306-6317.
[72] Okorokov AL, Warnock L, Milner J 
(2002) Effect of wild-type, S15D and 
R175H p53 proteins on DNA end-joining 
in vitro: Potential mechanism of DNA 
double-strand break repair modulation. 
Carcinogenesis 23: 549-557
[73] Stenmark-Askmalm M, Stal O, 
Sullivan S, Ferraud L, Sun XF, 
Carstensen J, Nordenskjold B. (1994) 
Cellular accumulation of p53 protein: 
An independent prognostic factor in 
stage II breast cancer. Eur. J Cancer 30A: 
175-180.
23
The Role p53 Protein in DNA Repair
DOI: http://dx.doi.org/10.5772/intechopen.99051
[74] Moll UM, LaOuglia M, Benard, 
Riou G. (1995) Wild-type p53 protein 
undergoes cytoplasmic sequestration in 
undifferentiated neuroblastomas but 
not in differentiated tumors. Proc. Natl. 
Acad. Sci. US, 92: 4407-4411.
[75] Bosari S, Viale G, Roncalli M, 
Graziani D, Borsani G, Lee AK, 
Coggi G. (1995) p53 gene mutations, p53 
protein accumulation and 
compartmentalization in colorectal 
adenocarcinoma. Am. J Pathol. 147: 
790-798.
[76] Bakhanashvili M. (2001) p53 
enhances the fidelity of DNA synthesis 
by human immunodeficiency virus type 
1 reverse transcriptase. Oncogene 20: 
7635-7644.
[77] Bakhanashvili M, Gedelovich R, 
Grinberg S, Rahav G. (2008) 
Exonucleolytic degradation of RNA by 
the tumor suppression protein p53 in 
cytoplasm. J Molec. Medicine 86: 75-88.
[78] Aloni-Grinstein R, Charni-Natan M, 
Solomon H, Rotter V. (2018) p53 and the 
viral connection: Back into the future. 
Cancers. 10 :178.
[79] Genini D, Sheeter D, Rought S, 
Zaunders JJ, Susin SA, Kroemer G, 
Richman DD, Carson DA, Corbeil J, 
Leoni LM. (2001) HIV induces 
lymphocyte apoptosis by a p53-initiated, 
mitochondrial- mediated mechanism. 
FASEB J. 15: 5-6.
[80] Bakhanashvili M, Hizi A (1992) 
Fidelity of the reverse transcriptase of 
human immunodeficiency virus type. 
FEBS Lett. 306: 151-156.
[81] Stumpf JD, Copeland WC. (2011) 
Mitochondrial DNA replication and 
disease: Insights from DNA polymerase 
γ mutations. Cell Mol Life Sci. 68: 
219-233.
[82] Wallace DC. (2010) Mitochondrial 
DNA mutations in disease and aging. 
Env. Mol. Mutagenesis 51:440-450.
[83] Singh KK, Kulawiec M. (2009) 
Mitochondrial DNA polymorphism and 
risk of cancer. Methods Mol Biol. 471: 
291-303.
[84] Katafuchi A, Nohmi T. (2010) DNA 
polymerases involved in the 
incorporation of oxidized nucleotides 
into DNA: Their efficiency and template 
base preference. Mut. Res. 703: 24-31.
[85] Mahyar-Roemer M, Fritzsche C, 
Wagner S, Laue M, Roemer K. (2004) 
Mitochondrial p53 levels parallel total 
p53 levels independent of stress 
response in human colorectal carcinoma 
and glioblastoma cells. Oncogene 23: 
6226-6236.
[86] Achanta G, Sasaki R, Feng L, 
Carew JS, Lu W, Pelicano H, et al. 
(2005) Novel role of p53 in maintaining 
mitochondrial genetic stability through 
interaction with DNA pol γ. EMBO J 24: 
3482-3492.
[87] de Souza-Pinto NC, Harris CC, 
Bohr VA. (2004) p53 functions in the 
incorporation step in DNA base excision 
repair in mouse liver mitochondria. 
Oncogene 23: 6559-6568.
[88] Wong TS, Rajagopalan S, 
Townsley FM, Freund SM, Petrovich M, 
Loakes D, Fersht AR. (2009) Physical 
and functional interactions between 
human mitochondrial single-stranded 
DNA binding protein and tumor 
suppressor p53. Nucleic Acids Res. 
37:568-581.
[89] Bakhanashvili M. Grinberg S, 
Bonda E, Simon AJ, 
Moshitch-Moshkovitz S, Rahav G. 
(2008) p53 in mitochondria enhances 
the accuracy of DNA synthesis. Cell 
Death Diff. 15: 1865-1874.
[90] Keating MJ. (1997) In: Nucleoside 
Analogs in Cancer Therapy. Cheson BD. 
Keating, Plunkett W. (eds). Marcel 
Dekker, Inc., New York, pp201-226.
P53 - A Guardian of the Genome and Beyond
24
[91] Sluis-Cremer N, Arion D, 
Parniak MA. (2000) Molecular 
mechanisms of HIV-1 resistance to 
nucleoside reverse transcriptase 
inhibitors (NRTIs). Cell. Mol. Life Sci. 
57:1408-1422.
[92] Zhou Y, Achanta G, Pelicano H, 
Gadhi V, Plunkett W, Huang P. (2002) 
Action of (E)-2’-Deoxy-2′-
(fluoromethylene) cytidine on DNA 
metabolism: Incorporation, excision and 
cellular response. Mol. Pharmacology 
61: 222-229.
[93] Feng L, Achanta G, Pelicano H, 
Zhang W, Plunkett W, Huang P. (2000) 
Role of p53 in cellular response to 
anticancer nucleoside analog-induced 
DNA damage. Int. J Molec. Medicine 5: 
597-604.
[94] Achanta G, Pelicano H, Feng L, 
Plunkett W, Huang P. (2001) Interaction 
of p53 and DNA-PK in response to 
nucleoside analogues: Potential role as a 
sensor complex for DNA damage. 
Cancer Res 61: 8723-8729.
[95] Sluis-Cremer N, Arion D, 
Parniak MA. (2000) Molecular 
mechanisms of HIV-1 resistance to 
nucleoside reverse transcriptase 
inhibitors (NRTIs). Cell. Mol. Life Sci. 
57:1408-1422.
[96] Bakhanashvili M, Novitsky E, 
Rubinstein E, Levy I, Rahav G. (2005) 
Excision of nucleoside analogs from 
DNA by p53 protein, a potential cellular 
mechanism of resistance to inhibitors of 
human immunodeficiency virus type 1 
reverse transcriptase. Antimic. Agents 
and Chem. 49:1576-1579.
[97] Bakhanashvili M, Grinberg S, 
Bonda E, Rahav G. (2009) Excision of 
nucleoside analogs in mitochondria by 
p53 protein. AIDS 23: 779-788.
[98] Fowler JD, Brown JA, Johnson KA, 
Suo Z. (2008) Kinetic investigation of 
the inhibitory effect of gemcitabine on 
DNA polymerization catalyzed by 
human mitochondrial DNA polymerase. 
J Biol. Chem. 283: 15339-15348.
[99] Lewis W, Day BJ, Copeland WC. 
(2003) Mitochondrial toxicity of NRTI 
antiviral drugs: An integrated cellular 
perspectives. Nature Reviews 2: 812-822.
[100] Olinski,R, Jurgowiak M, 
Zaremba TZ. (2010) Uracil in DNA–its 
biological significance. Mut. Res. 705 
239-245.
[101] Verri A, Mazzarello O, Spadari S, 
Focher R. (1992) Uracil-DNA 
glycosylases preferentially excise 
mispaired uracil. Biochem. J 287: 
1007-1010.
[102] Longley DB, Harkin DP, 
Johnston PG. (2003) 5-fluorouracil: 
Mechanisms of action and clinical 
strategies. Nat.Rev. Cancer. 3: 330-338.
[103] Kennedy EM, Daddacha W, 
Slater R, et al. (2011) Abundant non-
canonical dUTP found in primary 
human macrophages drives its frequent 
incorporation by HIV-1 reverse 
transcriptase. J Biol. Chem. 286: 
25047-25055.
[104] Hansen EC, Ransom M, 
Hesselberth JR. et al. (2016) Diverse 
fates of uracilated HIV-1 DNA during 
infection of myeloid lineage cells. Elife 
5 e18477.
[105] Saragani Y, Hizi A, Rahav G, 
Zauch S, Bakhanashvili M. (2018) 
Cytoplasmic p53 Contributes to the 
Removal of Uracils Misincorporated by 
HIV-1 Reverse Transcriptase. Biochem 
Biophys Res Commun. 497: 804-810.
[106] Bonda E, Rahav G, Kaya A, 
Bakhanashvili M. (2016) p53 in the 
mitochondria, as a trans-acting protein, 
provides error-correction activities 
during the incorporation of non-
canonical dUTP into DNA. Oncotarget 
7: 73323-73336.
25
The Role p53 Protein in DNA Repair
DOI: http://dx.doi.org/10.5772/intechopen.99051
[107] Zhou ZX, Williams JS, Lujan SA, 
Kunkel TA. (2021) Ribonucleotides 
incorporation into DNA during DNA 
replication and its consequences. Crit 
Rev Biochem. Mol. Biol. 56:109-124.
[108] Cerritelli SM, El Hage A. (2020) 
RNases H1 and H2: guardians of the 
stability of the nuclear genome when 
supply of dNTPs is limiting for DNA 
synthesis. Curr Genet. 66:1073-1084.
[109] Akua T, Rahav G, Saragani Y, 
Hizi A, Bakhanashvili M. (2017) Tumor 
suppressor p53 protein removes 
ribonucleotides from DNA incorporated 
by HIV-1 reverse transcriptase. AIDS 
31:343-353.
[110] Lilling G, Novitsky E, Sidi Y, 
Bakhanashvili M. (2003) p53-associated 
3′→5′ exonuclease activity in nuclear 
and cytoplasmic compartments of the 
cells. Oncogene 22: 233-245.
[111] Bakhanashvili M, Novitsky E, 
Lilling G, Rahav G. (2004) p53 in 
cytoplasm may enhance the accuracy of 
DNA synthesis by human 
immunodeficiency virus type 1 reverse 
transcriptase. Oncogene 23: 6890-6899.
[112] Kulawiec, M., Ayyasamy, V., Singh, 
K.K. (2009). p53 regulates mtDNA copy 
number and mitocheckpoint pathway. J 
Carcinog.8, 8
[113] Ahn J, Poyurovsky MV, Baptiste N, 
Beckerman R, Cain C, Mattia M, et al. 
(2009) Dissection of the sequence-
specific DNA binding and exonuclease 
activities reveals a superactive yet 
apoptotically impaired mutant p53 
protein. Cell Cycle 8: 1603-1615.
